Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLGN4X siRNA
- Development stage
- Preclinical
- Lead developer
- Alabama State University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
NLGN4X siRNA is a small interfering RNA designed to knock down the expression of neuroligin 4X (NLGN4X), a neural cell adhesion molecule. In preclinical breast cancer models, particularly triple-negative breast cancer (TNBC), NLGN4X is highly expressed and associated with a mesenchymal phenotype and decreased relapse-free survival. Transfection of breast cancer cells (such as MDA-MB-231) with NLGN4X siRNA significantly decreases cell proliferation and migration while inducing apoptosis, as evidenced by elevated caspase 3/7 and cleaved PARP. This suggests NLGN4X siRNA serves as a valuable research tool to investigate NLGN4X as a potential therapeutic target and biomarker in breast cancer progression and metastasis.
- Other names
- NLGN4X-specific siRNANLGN-4X-specific siRNANLGN 4X-specific siRNAneuroligin 4X siRNAneuroligin4X siRNAneuroligin-4X siRNA
02
Targets
NLGN4X (Neuroligin-4, X-linked)
Beyond the preview
Go deeper on NLGN4X siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLGN4X siRNA.